AZOPHARMA OFFERS SERVICES TO EUROPEAN MARKET
June 2, 2007
Miramar, FL – Azopharma announces a European branch of their contract pharmaceutical development services. Ms. Carole Delauney, based out of France, will represent the Azopharma Product Development Group, a network of six companies offering contract services from preclinical through manufacturing. “Pharmaceutical companies in Europe now have local representation to facilitate access to the compelling solutions in contract drug development services offered by our group of companies,” says Mr. Phil Meeks, CEO.
The Azopharma Product Development Group includes:
Azopharma Contract Services – Integrated product development and CTM manufacturing – www.azopharma.com
IQsynthesis – Synthetic chemistry services from discovery to clinical materials – www.iqsynthesis.com
ApiCross Drug Delivery – Proprietary drug delivery platforms for insoluble compounds – www.apicross.com
Aniclin Preclinical Services – Preclinical services in support of early product development – www.aniclin.com
Cyanta Drug Development – Analytical chemistry services from development to QC testing – www.cyanta.com
AvivoClin Clinical Services – Human clinical pharmacology services for Phase I clinical trials – www.avivoclin.com
“European companies can now manage their pipeline by either outsourcing a single aspect to one of these providers, or by turning to Azopharma for their entire developmental program. With a full range of services this portfolio offers the European pharmaceutical and medical device industry the opportunity for flexible and specialized contract outsourcing, an emerging trend that is transforming the pharmaceutical industry. The experience and expertise in drug development that Ms. Carole Delauney brings to our Company will enable fruitful discussions and facilitation of pharmaceutical development for our European Customers,” continued Mr. Meeks. Ms. Delauney added, “I am delighted to join such a prestigious and internationally recognized organization. The resources and scope of services offered by the Azopharma Product Development Group will be well received in the European community.”
About Azopharma
All companies in the Azopharma Product Development Group of companies are wholly owned subsidiaries of Azopharma Contract Services, Inc. The group collectively consists of over 250 scientists providing contract research services both domestically and internationally. All companies are owned by a holding company, Chemir, Inc., based in St. Louis Missouri. Chemir, Inc. is owned by Dr. Shri Thanedar who serves as Chairman of all of the companies in the Azopharma product development group of companies.
Contact
Phil Meeks, CEO
Azopharma Product Development Group
10320 USA Today Way
Miramar, Florida 33025
(954) 433-7480